


Claims

1. A dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor whose solubility is slight, comprising the PDE 4 inhibitor whose solubility is slight together with polyvinylpyrrolidone as binder, and one or more other suitable pharmaceutical excipients.
2. The dosage form as claimed in claim 1, where the pharmaceutical excipients are excipients from the group of fillers, binders and lubricants or release agents.
3. The dosage form as claimed in claim 1, which is a solid oral dosage form with immediate release of active ingredient (immediate release solid oral dosage form).
4. The dosage form as claimed in claim 1, which is a tablet.
5. The dosage form as claimed in claim 1, where the PDE 4 inhibitor whose solubility is slight is a compound having a solubility in water of less than or equal to 100 milligram/liter at a temperature of from 15 to 25°C.
6. The dosage form as claimed in claim 1, where the PDE 4 inhibitor is a compound selected from the group of compounds of the formula I



in which either

R1 is 3-7C cycloalkoxy, 3-7C cycloalkylmethoxy or benzyloxy and
 R2 is 1-4C alkoxy which is completely or partly substituted by fluorine,
 or
 R1 is 1-4C alkoxy which is completely or partly substituted by fluorine and
 R2 is 3-7C cycloalkylmethoxy or benzyloxy,
 and
 R3 is phenyl, pyridyl, phenyl substituted by R31, R32 and R33, or pyridyl substituted by

R34, R35, R36 and R37, where

R31 is hydroxyl, halogen, cyano, carboxyl, trifluoromethyl, 1-4C alkyl, 1-4C alkoxy, 1-4C alkoxy carbonyl, 1-4C alkyl carbonyl, 1-4C alkyl carbonyloxy, amino, mono- or di-1-4C alkylamino or 1-4C alkyl carbonylamino,

R32 is hydrogen, hydroxyl, halogen, amino, trifluoromethyl, 1-4C alkyl or 1-4C alkoxy,

R33 is hydrogen, halogen, 1-4C alkyl or 1-4C alkoxy,

R34 is hydroxyl, halogen, cyano, carboxyl, 1-4C alkyl, 1-4C alkoxy, 1-4C alkoxy carbonyl or amino,

R35 is hydrogen, halogen, amino or 1-4C alkyl,

R36 is hydrogen or halogen and

R37 is hydrogen or halogen,

the salts of these compounds and the N-oxides of the pyridines and the salts thereof.

7. The dosage form as claimed in claim 6, which comprises a compound of the formula I in which
R1 is difluoromethoxy,
R2 is cyclopropylmethoxy and
R3 3,5-dichloropyrid-4-yl,
the salts of this compound, and the N-oxide of the pyridine and salts thereof.
8. A process for producing a dosage form as claimed in claim 1, comprising the steps:
(a) production of a mixture of PDE 4 inhibitor and pharmaceutical excipients and (b) granulation of the mixture obtained in (a) with an aqueous solution of PVP.
9. A process for producing a dosage form as claimed in claim 1, comprising the steps:
(a) production of a mixture of pharmaceutical excipients and
(b) granulation of the mixture obtained in (a) with a suspension of the active ingredient in an aqueous solution of PVP.
10. A process for producing a dosage form as claimed in claim 1, comprising the production of a solid solution of PVP and PDE 4 inhibitor whose solubility is slight.
11. A method for the treatment or prophylaxis of a disease regarded as treatable or preventable by PDE 4 inhibitors, wherein a dosage form as claimed in claim 1 is administered.